Target intelligence / Profile preview

Phosphoinositide 3-kinase catalytic subunit gamma (p110γ) (p110γ)

Target
p110γ
Molecular classification
Enzyme, Kinase, Lipid kinase, Phosphoinositide 3-kinase (PI3K) family, Class IB PI3K
01

Overview

p110γ, encoded by the PIK3CG gene, is the catalytic subunit of the Class IB phosphoinositide 3-kinase (PI3Kγ) enzyme (NIH, 2026). Unlike Class IA PI3Ks which are typically activated by receptor tyrosine kinases, p110γ is primarily activated by G protein-coupled receptors (GPCRs) through interaction with Gβγ subunits (NIH, 2026). It is highly expressed in immune cells, where it regulates critical processes such as chemotaxis, cell migration, and inflammatory responses (NIH, 2026). In the context of oncology, p110γ is a major driver of immune suppression within the tumor microenvironment by promoting the recruitment and polarization of myeloid-derived suppressor cells and M2-type macrophages (NIH, 2021). Pharmacological inhibition of p110γ, using agents like eganelisib, is being explored to reprogram the tumor immune landscape and enhance the efficacy of immunotherapies (ClinicalTrials.gov, 2024). Additionally, its role in leukocyte recruitment makes it a therapeutic target for various inflammatory and autoimmune conditions such as rheumatoid arthritis and asthma (NIH, 2009).

Other names
PIK3CGp110-gammaPI3K-gammaPI3KγPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformPhosphoinositide 3-kinase catalytic subunit gamma
02

Mechanism of action

ATP-competitive inhibition of the p110γ catalytic subunit, which prevents the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), thereby blocking downstream Akt/mTOR signaling and modulating immune cell trafficking and polarization.

03

Biological functions

Signal transductionImmune cell signalingChemotaxisCell migrationCell proliferationMyeloid cell invasionAngiogenesisMast cell degranulation
04

Disease associations

CancerInflammationRheumatoid arthritisAsthmaChronic obstructive pulmonary disease (COPD)Multiple sclerosisCardiovascular diseaseAcute myeloid leukemia (AML)Pancreatic ductal adenocarcinomaHepatocellular carcinoma
05

Safety considerations

Hepatotoxicity (elevated liver enzymes)Gastrointestinal toxicity (diarrhea, colitis)Skin rashNeutropeniaIncreased risk of infectionHyperglycemia
06

Interacting drugs

Eganelisib (IPI-549)

8 more in the full profile.

07

Biomarkers

PIK3CG expression levelsPhospho-Akt (p-Akt) levelsM2/M1 macrophage ratioMyeloid-derived suppressor cell (MDSC) levelsTNFα production

Beyond the preview

Go deeper on Phosphoinositide 3-kinase catalytic subunit gamma (p110γ) (p110γ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphoinositide 3-kinase catalytic subunit gamma (p110γ) (p110γ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call